Bear, this might shed some light...

"On behalf of all members of the BETonMACE CSC, Professor Kausik Ray welcomed the addition of US-based sites to the ongoing cardiovascular disease (CVD) outcomes trial, BETonMACE. The BETonMACE trial will now be expanded beyond Europe, Asia and South America to a fourth continent – North America with the addition of the United States. Prof. Ray commented, “The addition of the United States is timely as we plan to conduct a Sample Size Recalculation Analysis ('SSRA') later in the first half of 2018...."

Speaking on behalf of the Clinical Steering Committee Dr. Ray said "we" plan to conduct a SSRA....he's not speaking on behalf of Resverlogix, but on behalf of the CSC.